期刊文献+

金纳米微粒作探针共振瑞利散射法测定某些蒽环类抗癌药物 被引量:13

Resonance Rayleigh Scattering Method for the Determination of Some Anthracycline Anticancer Drugs with Gold Nanoparticle as Probe
下载PDF
导出
摘要 在近中性至弱碱性介质中,金纳米微粒与表柔比星(EPI)、柔红霉素(DNR)和米托蒽醌(MXT)等蒽环类抗癌药物借静电引力、疏水作用力结合,形成粒径更大的聚集体,导致共振瑞利散射(RRS)的显著增强并产生新的RRS光谱,三种结合产物的最大RRS峰均位于313nm附近,并在510~610nm之间有一宽的散射带.其散射强度(ΔI)与3种抗癌药物的浓度成正比,对EPI,DNR和MXT的线性范围分别为0.009~0.50,0.010~0.70和0.030~1.20μg·mL-1,它们的检出限(3σ)分别为2.7,3.1和9.0ng·mL-1.研究了反应产物的吸收、荧光和RRS光谱特征,适宜的反应条件及分析化学性质,发展了一种用RRS技术灵敏、简便、快速测定蒽环类抗癌药物的新方法. In a neutral or weak alkaline medium, the gold nanoparticle can combine with an anthracycline anticancer drugs such as epirubicin, daunorubicin or mitoxantrone by the virtue of electrostatic and hydrophobic interaction, forming aggregate with bigger diameters. As a result, the resonance Rayleigh scattering (RRS) was enhanced greatly, and a new RRS spectrum appeared. The maximum RRS signals of three ion-association complexes were all located at about 313 nm, and there were another wide scattering strip between 510-610 nm. There was a linear relationship between the RRS intensity and the drug concentration in the range of 0.009-0.5 for epirubicin (EPI), 0.010-0.7 for daunorubicin (DNR) and 0.030-1.2 ug·mL^-1 for mitoxantrone (MXT), respectively. Their detection limits (3σ) for three drugs were 2.7 for epirubicin, 3.1 for daunorubicin and 9.0 ng·mL^-1 for mitoxantrone. In this work, the characteristics of the absorption, fluorescence and RRS spectra, the optimum conditions of the reaction and the properties of analyrical chemistry were investigated. A sensitive, simple and new method for the determination of anthracycline anticancer drugs based on RRS has been developed.
出处 《化学学报》 SCIE CAS CSCD 北大核心 2007年第9期821-828,共8页 Acta Chimica Sinica
基金 国家自然科学基金(No.20475045)资助项目.
关键词 金纳米微粒 共振瑞利散射 蒽环类抗癌药物 gold nanoparticle resonance Rayleigh scattering anthracycline anticancer drug
  • 相关文献

参考文献23

  • 1周际昌.抗癌药物的临床应用[M].北京:化学工业出版社,2003.132-134.
  • 2Bozdag,S.;Capan,Y.;Vural,I.;Hincal,A.A.J.Acta Pharm.Turc.2004,46,43.
  • 3Chin,D.L.;Lure,B.L.;Sikic,B.I.J.Chromatogr.B 2002,779,259.
  • 4Hu,Q.;Zhang,L.;Zhou,T.-S.;Fang,Y.-Z.Anal.Chim.Acta 2000,416,15.
  • 5Griese,N.;Blaschke,G.;Boos,J.;Hempel,G.J.Chromatogr.A 2002,979,379.
  • 6Golabi,S.M.;Hassan-Zadeh,V.Talanta 1996,43,397.
  • 7Lachatre,F.;Marquet,P.;Ragot,S.;Gaulier,J.M.;Cardot,P.;Dupuy,J.L.J.Chromatogr.B 2000,738,281.
  • 8Alykov,N.M.;Nekrest Yanova,T.V.;Yakovleva,L.V.Zh.Ahal.Khim.1991,46,1642.
  • 9赵刚,胡增华,黄力明,祁静蕙.荧光光谱法测定人血浆中国产阿霉素浓度及临床药代动力学观察[J].云南医药,1994,15(5):377-379. 被引量:9
  • 10Chilukuri,S.P.S.;Jana,S.V.M.;Lingeswara,R.Talanta 1996,43,1827.

二级参考文献102

共引文献239

同被引文献177

引证文献13

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部